Study of Escitalopram in the Treatment of Specific Phobia

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Inclusion Criteria:

• Adults 18-65 years of age
• DSM-IV criteria for specific phobia according to the MINI
• For women of childbearing potential, a negative serum pregnancy test at screening
• Written informed consent

Exclusion Criteria:

• Any current primary DSM-IV diagnosis other than specific phobia
• History of DSM-IV substance abuse or dependence within the last months
• Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
• Suicide risk or serious suicide attempt within the last year
• Clinically significant laboratory or EKG abnormality or unstable medical condition
• For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
• Subjects needing concurrent use of psychotropic medications